NCT02595892 2026-03-18
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
70 trialsNCT03348631 2026-03-18
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05554328 2026-03-18
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05554367 2026-03-18
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05564377 2026-03-18
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03412877 2026-03-17
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT02345265 2026-03-05
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01174121 2026-03-04
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06503146 2025-11-12
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT02498600 2025-08-29
Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT05185947 2025-03-07
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT03602586 2024-07-26
Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT04102436 2024-03-12
Non-Viral TCR Gene Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT02059265 2023-08-01
Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02203513 2022-09-10
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01199263 2020-09-16
Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00979992 2020-02-19
Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03300843 2019-12-13
Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01766622 2019-12-04
18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT01196429 2019-08-08
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01540565 2019-07-23
Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01010126 2019-01-25
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00301756 2018-08-20
Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00001426 2018-04-05
A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00001827 2017-10-06
p53 Vaccine for Ovarian Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01175343 2017-05-24
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02417753 2017-05-15
AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00550654 2017-01-13
Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01283035 2016-06-24
A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00072566 2015-05-12
Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00039585 2015-04-30
Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003718 2014-01-06
Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00096239 2013-12-19
CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00021385 2013-12-18
Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00025441 2013-12-04
Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003634 2013-11-06
Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00004064 2013-11-06
Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00005025 2013-11-06
Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00017303 2013-11-06
Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00036712 2013-09-20
Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00002487 2013-09-17
Methotrexate Plus Dipyridamole in Treating Patients With Advanced Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00838656 2013-09-17
Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00004876 2013-08-26
Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00964626 2013-08-26
Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01100372 2013-08-26
Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00003732 2013-08-12
Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00305838 2013-08-12
CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00014690 2013-08-02
ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00748527 2013-07-10
Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00004008 2013-06-26
Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer
National Cancer Institute (NCI)
Phase 2 Completed